Voloridge Investment Management
CRSP icon

Voloridge Investment Management’s CRISPR Therapeutics CRSP Stock Holding History

Voloridge Investment Management’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-32,388
Closed -$2.1M – 1182
2025
Q3 		$2.1M Buy
+32,388
New +$1.86M 0.01% 933
2025
Q1 		– Sell
-52,835
Closed -$2.08M – 1202
2024
Q4 		$2.08M Sell
52,835
-113,428
-68% -$5.36M 0.01% 939
2024
Q3 		$7.81M Buy
+166,263
New +$8.44M 0.03% 655
2024
Q2 		– Sell
-44,312
Closed -$3.02M – 1225
2024
Q1 		$3.02M Sell
44,312
-682,575
-94% -$48.9M 0.01% 763
2023
Q4 		$45.5M Buy
+726,887
New +$40.2M 0.18% 156
2023
Q3 		– Sell
-25,642
Closed -$1.44M – 1414
2023
Q2 		$1.44M Sell
25,642
-40,482
-61% -$2.3M 0.01% 1046
2023
Q1 		$2.99M Buy
+66,124
New +$3.21M 0.01% 845
2022
Q4 		– Sell
-15,380
Closed -$1M – 1469
2022
Q3 		$1M Sell
15,380
-132,710
-90% -$9.62M 0.01% 1163
2022
Q2 		$9M Sell
148,090
-231,144
-61% -$13.6M 0.05% 479
2022
Q1 		$23.8M Buy
379,234
+163,605
+76% +$10.3M 0.14% 219
2021
Q4 		$16.3M Buy
215,629
+212,906
+7,819% +$18.6M 0.09% 318
2021
Q3 		$305K Sell
2,723
-1,860
-41% -$234K ﹤0.01% 1530
2021
Q2 		$742K Sell
4,583
-36,676
-89% -$4.46M 0.01% 1344
2021
Q1 		$5.03M Buy
41,259
+12,068
+41% +$1.82M 0.04% 531
2020
Q4 		$4.47M Buy
+29,191
New +$3.45M 0.04% 487
2020
Q1 		– Sell
-59,617
Closed -$3.63M – 1139
2019
Q4 		$3.63M Buy
+59,617
New +$3.26M 0.07% 352
2019
Q1 		– Sell
-62,580
Closed -$1.79M – 950
2018
Q4 		$1.79M Buy
+62,580
New +$2.18M 0.08% 209

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
GP
GSK plc London $599M AUM
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Voloridge Investment Management's CRSP Position: Q4 2025 in Review

Voloridge Investment Management sold out of CRISPR Therapeutics (CRSP) in Q4 2025, closing a stake of 32,388 shares — an estimated $2.1M sold.

Voloridge Investment Management first reported a position in CRSP in Q4 2018 and held it in 17 quarters. The position peaked at $45.5M in Q4 2023. 479 funds tracked by Wall St. Rank hold CRSP as of Q4 2025.

  • Voloridge Investment Management reported no remaining CRISPR Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Voloridge Investment Management sold 32,388 CRISPR Therapeutics shares in Q4 2025, an estimated $2.1M.
  • Voloridge Investment Management first reported a position in CRISPR Therapeutics in Q4 2018 and held it in 17 quarters.
  • Voloridge Investment Management's CRISPR Therapeutics position peaked at $45.5M in Q4 2023.
  • 479 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q4 2025.

Based on Voloridge Investment Management's 13F filing for Q4 2025, filed 17 Feb 2026.